Literature DB >> 25500316

Vaccines to prevent tuberculosis infection rather than disease: Physiological and immunological aspects.

Ian M Orme1.   

Abstract

There is increasing enthusiasm and optimism that a vaccine could be developed that prevents infection rather than disease. In this article I discuss the fact that despite this optimism nothing has been produced so far that seems to have this capability, and moreover even the borderline between when infection ends and disease begins has not even been defined. To be effective such a vaccine, or at least the immunity it would generate, would have to work within the confines of the pulmonary physiological systems, which are complex. To date much of the emphasis here has turned away from T cell mediated immunity and towards establishing specific antibodies in the lungs. Here, I argue that with the exception of a possible exclusionary function, most claims of a protective role of antibody are completely over-blown. Finally, even if we had a potential "anti-infection" vaccine, how would we test and validate it?
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal modeling; Anti-infection vaccine; Tuberculosis; Vaccination

Mesh:

Substances:

Year:  2014        PMID: 25500316     DOI: 10.1016/j.tube.2014.10.008

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  10 in total

Review 1.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

2.  Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

Authors:  A J Graves; D A Hokey
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Antibodies and tuberculosis.

Authors:  Ashley J Jacobs; Juthathip Mongkolsapaya; Gavin R Screaton; Helen McShane; Robert J Wilkinson
Journal:  Tuberculosis (Edinb)       Date:  2016-08-26       Impact factor: 3.131

4.  GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.

Authors:  Thomas H King; Crystal A Shanley; Zhimin Guo; Donald Bellgrau; Timothy Rodell; Synthia Furney; Marcela Henao-Tamayo; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

Review 5.  Trying to See the Forest through the Trees: Deciphering the Nature of Memory Immunity to Mycobacterium tuberculosis.

Authors:  Ian M Orme; Marcela I Henao-Tamayo
Journal:  Front Immunol       Date:  2018-03-08       Impact factor: 7.561

6.  Clinical Significance of M1/M2 Macrophages and Related Cytokines in Patients with Spinal Tuberculosis.

Authors:  Liang Wang; Xiaoqian Shang; Xinwei Qi; Derong Ba; Jie Lv; Xuan Zhou; Hao Wang; Nazierhan Shaxika; Jing Wang; Xiumin Ma
Journal:  Dis Markers       Date:  2020-05-20       Impact factor: 3.434

7.  Mycobacterium tuberculosis-specific CD4+ and CD8+ T cells differ in their capacity to recognize infected macrophages.

Authors:  Jason D Yang; Daniel Mott; Rujapak Sutiwisesak; Yu-Jung Lu; Fiona Raso; Britni Stowell; Greg Hunter Babunovic; Jinhee Lee; Steve M Carpenter; Sing Sing Way; Sarah M Fortune; Samuel M Behar
Journal:  PLoS Pathog       Date:  2018-05-21       Impact factor: 6.823

Review 8.  Lipoarabinomannan in Active and Passive Protection Against Tuberculosis.

Authors:  Margarida Correia-Neves; Christopher Sundling; Andrea Cooper; Gunilla Källenius
Journal:  Front Immunol       Date:  2019-09-11       Impact factor: 7.561

9.  Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model.

Authors:  Nawamin Pinpathomrat; Naomi Bull; Janet Pasricha; Rachel Harrington-Kandt; Helen McShane; Elena Stylianou
Journal:  Vaccine       Date:  2021-02-03       Impact factor: 3.641

10.  Biology of clinical strains of Mycobacterium tuberculosis with varying levels of transmission.

Authors:  Crystal A Shanley; Marcela I Henao-Tamayo; Chand Bipin; Raja Mugasimangalam; Deepshika Verma; Diane J Ordway; Elizabeth M Streicher; Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2018-02-09       Impact factor: 3.131

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.